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a  b  s  t  r  a  c  t
Tuberculosis  (TB)  remains  one  of  the  most  important  infectious  diseases  of  man  and animals,  and  the  only
available  vaccine  (BCG)  requires  urgent  replacement  or improvement.  To  facilitate  this,  the  protective
mechanisms  induced  by  BCG  require  further  understanding.  As  a live  attenuated  vaccine,  persistence  of
BCG bacilli  in  the host  may  be a crucial  mechanism.
We  have  investigated  the  long  term  persistence  of BCG  following  vaccination  and  the  inﬂuence  on  the
induced  immune  response  and  protection,  using an  established  murine  model.  We  sought  to establish
whether  previously  identiﬁed  BCG-speciﬁc  CD4 TEM cells represent  genuine  long-lived  memory  cells of
a relatively  high  frequency,  or are  a consequence  of  continual  priming  by  chronically  persistent  BCG
vaccine  bacilli.
By  clearing  persistent  bacilli,  we  have  compared  immune  responses  (spleen  and  lung  CD4:  cytokine
producing  T effector/TEM; TCR-speciﬁc)  and  BCG-induced  protection,  in  the  presence  and  absence  of these
persisting  vaccine  bacilli.  Viable  BCG bacilli  persisted  for at least  16  months  post-vaccination,  associated
with  speciﬁc  CD4  T effector/TEM and  tetramer-speciﬁc  responses.  Clearing  these  bacilli  abrogated  all
BCG-speciﬁc  CD4  T cells  whilst  only  reducing  protection  by  1 log10.
BCG  may  induce  two additive  mechanisms  of immunity:  (i) dependant  on  the  presence  of  viable  bacilli
and TEM; and  (ii)  independent  of  these  factors.
These data  have crucial  implications  on  the  rational  generation  of  replacement  TB  vaccines,  and  the
interpretation  of BCG induced  immunity  in animal  models.
Crown  Copyright  © 2014  Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the CC. Introduction
Tuberculosis (TB) caused by infection with Mycobacterium tuber-
ulosis (M.  tb)  or Mycobacterium bovis (M.  bovis) remains one of the
ost important infectious diseases of man  and animals, respec-
ively; inﬂicting a huge cost in both health, welfare and ﬁnancial
erms [1].
At present the only vaccine against TB is M.  bovis bacille
almette–Guérin (BCG), which demonstrates variable efﬁcacy in
umans and cattle [2,3]. In particular, BCG appears effective in
hildhood, but not in adolescents and adults [4]. Despite this per-
ormance, BCG remains the most widely used human vaccine, and
ue to its partial efﬁcacy and proven safety record, is unlikely to be
ithdrawn and remains the benchmark to improve upon.
It is clear that optimal protection against TB requires CD4 T cells,
s well as the effector cytokines IFN- and TNF- (reviewed in [5]).
∗ Corresponding author. Tel.: +44 0 1932 359557; fax: +44 0 1932 357260.
E-mail address: philip.hogarth@apha.gsi.gov.uk (P.J. Hogarth).
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264-410X/Crown Copyright © 2014 Published by Elsevier Ltd. This is an open 
icenses/by-nc-nd/3.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
However, as other studies demonstrate; CD4 T cell derived IFN- is
not an exclusive component of vaccine-mediated immunity [6] and
identiﬁcation of other critical components of protection remains
elusive.
To compound our incomplete knowledge, the study of BCG
induced immune memory has also proven difﬁcult. The chronic
nature of TB infection, lack of sterilising immunity, and transient
protective window, all contribute to complicate the characterisa-
tion of vaccine-speciﬁc T cell memory.
Memory T cells exist in a number of subsets. Classically, these
are understood to be partitioned into effector memory (TEM) and
central memory (TCM) categories [7]; but recent evidence argues for
a complex functional diversity within these two broad categories
in vivo (reviewed in [8]).
There has been an intensive effort to characterise T cell mem-
ory induced by BCG immunization in both animal models [9–14]
and humans [15–17]. Given its variable efﬁcacy, it is of crit-
ical importance to understand the mechanisms underlying its
protective capacity, if improved vaccines or vaccination strategies
are to be progressed.
access article under the CC BY-NC-ND license (http://creativecommons.org/
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The majority of these studies report BCG to induce a pre-
ominant CD4 TEM response, deﬁned by CD62Llo expression,
ften associated with cytokine multifunctionality [9,16,18]; but
ew identify BCG-speciﬁc CD62Lhi or CCR7hi CD4 TCM responses
19–22]. We  recently reported CD4 TEM cells to persist 18 months
ollowing BCG immunization [9], and consistently, observe no
eﬁned contraction of immune responses following immunization.
Given the potential of BCG to persist in the immuno-competent
ost [23–27], combined with the absence of immune contraction;
e hypothesised whether these CD4 TEM cells represent: (a) gen-
ine long-lived high frequency memory cells, or alternately; (b)
esult from continual priming by persistent BCG bacilli.
Therefore, we sought to investigate the persistence of live BCG
ong after immunization and the inﬂuence of this on immune
esponses and protection against M.  bovis challenge, in a mouse
odel [28].
We report here that live BCG vaccine persisted for the 16 month
eriod of study and that clearance of these bacilli by antibiotic
reatment resulted in abrogation of the BCG-speciﬁc CD4 T cell pop-
lation; but protective immunity was only reduced by ∼50%. Thus,
e propose the existence of two separate additive mechanisms of
rotection induced by BCG; one dependent on, and one indepen-
ent of persistent BCG and associated TEM population. These data
ay  have crucial implications on the rational generation of replace-
ent or adjunct TB vaccines, and the interpretation of BCG induced
mmunity in animal models.
. Materials and methods
.1. Ethics
All animal work was carried out in accordance with the UK Ani-
al  (Scientiﬁc Procedures) Act 1986; under appropriate licences.
he study protocol was approved by the AHVLA Animal Use Ethics
ommittee (UK PCD number 70/6905).
.2. Animals
Female BALB/c mice were obtained from SPF facilities at Charles
iver UK Ltd and used at 8 weeks of age. All animals were housed
n appropriate BSL3 containment facilities at AHVLA.
.3. Mycobacteria
The vaccination strain was the human vaccine M. bovis BCG
anish 1331, prepared as per manufacturer’s instructions (SSI,
enmark).
Mycobacterium bovis isolate AF2122/97 was used for all chal-
enge experiments as previously described [9].
.4. Mycobacterial antigens
A pool of 7 recombinant mycobacterial proteins (Rv1886c,
v0251, Rv0287, Rv0288, Rv3019c, Rv3763, Rv3804c), were used
or all stimulations as previously described [9]. All proteins were
xtensively dialyzed and re-suspended in physiological buffer
HBSS) before use.
.5. Immunization, mycobacterial enumeration and challenge
Mice were immunized with a single intradermal injection
50 l) containing 2 × 105 CFU of BCG, or sham control (HBSS) in
he base of the tail. For enumeration of viable BCG, the spleen, lung,
iver and the pooled LNs draining the site of immunization [29]
inguinal, iliac and axillary) were aseptically removed, homoge-
ized and plated in their entirety onto modiﬁed Middlebrook 7H112 (2014) 6911–6918
agar (DifcoTM) plates [30]. CFU were enumerated twelve weeks
after incubation at 37 ◦C. Limit of detection (LOD) was 2 CFU. A
sample of colonies at 16 months was veriﬁed as BCG by molecular
typing [31].
Additionally, thirty weeks following immunization, mice were
challenged intranasally with ∼600 CFU of M.  bovis as previously
described [28]. Bacterial loads in spleen and lungs were enumer-
ated four weeks after challenge as previously described [28].
2.6. Antibiotic clearance of BCG bacilli (BCG abbreviated)
Drinking water containing antibiotics (100 g/ml ethambutol,
200 g/ml isoniazid and 100 g/ml rifampicin) (all Sigma, UK), was
provided ad libitum, replenished twice weekly for the period of
treatment. Placebo comprised D.H2O containing the same volume
of solvent (DMSO) used to prepare antibiotics.
2.7. Cell isolations and stimulations
On euthanasia, spleen, lung and LNs (inguinal, iliac, axillary,
brachial, cervical and popliteal) were aseptically removed and
spleen and interstitial lung cells prepared as previously described
[9]. LN cells were prepared as spleen cells. Following wash-
ing (300 g/8 min), all cells were re-suspended at 5 × 106 ml−1 for
assays. Cells were cultured with the speciﬁc protein cocktail as
described, each antigen at ﬁnal concentration of 2 g/ml for all
assays.
2.8. ELISPOT
Cells were incubated with antigen and the frequency of antigen-
speciﬁc IFN- secretors detected by ELISPOT (Mabtech, Sweden), as
previously described [9].
2.9. Flow cytometry
For intracellular staining (ICS), cells isolated from spleen or
lungs were stimulated with antigen pool and anti-CD28 (BD Bio-
sciences) as previously described [9]. They were surface stained
with CD4–APC-H7, CD19-PE-CF594, CD11b-PE-CF594 (all BD Bio-
science), CD44–eFluor 450, CD62L – PE or – PerCP-Cy5.5, CD27–PE
and LIVE/DEAD® Fixable Yellow Dead Cell Stain (‘YeViD’, Invitro-
gen). Subsequently, cells were washed, ﬁxed and permeabilised and
stained for ICS with IFN-–APC (BD Bioscience), IL-2–PE-Cy7 and
TNF-–FITC as previously described [9].
For MHC  class II-peptide tetramer staining, RBC were removed
(spleen samples only) using RBC lysis buffer (eBioscience, USA).
Cells were stained (45 min/37 ◦C/5% CO2) in culture media with
Rv0288 (TB10.4) peptide: MHCII I-A(d) (SSTHEANTMAMMARDT)
tetramer-complex, labeled with APC; or I-A(d) negative control
(PVSKMRMATPLLMQA) tetramer–APC (both provided by NIH MHC
Tetramer Core Facility, USA). Following washing, they were stained
(15 min/4 ◦C) in staining buffer with CD4–APC-H7, CD44–FITC,
CD62L–PerCP-Cy5.5, and YeViD, washed and ﬁxed with Cytoﬁx.
All antibody conjugates were purchased from eBioscience
except where stated. Data were acquired using a Beckman Coulter
CyAn ADP (retroﬁtted with a 562/40 bandpass ﬁlter in the second
channel of the violet laser) and analyzed on Summit v4.3 (Beck-
man Coulter, USA) or Flowjo v7.6.5 (Tree Star, USA) software. All
analyses were gated on a minimum of 100,000 live lymphocytes.
2.10. Statistical analysesAll data were analyzed with GraphPad Prism 5 software (Graph-
Pad, USA) using un-paired student’s two-sided t-test (2 treatment
groups) or one- or two-way ANOVA with Bonferroni post-test (3
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Fig. 1. BCG-bacilli and -speciﬁc IFN- response persist for at least 16 months in the
vaccinated host and demonstrate a deﬁned correlation. (A) Sequential mycobacterial
burden in d.LNs, spleen and lung of mice after immunization with BCG. Sym-
bols represent mean (±S.E.) CFU (LOD = 2 CFU, n = 7–8). (B) The frequency of BCG
antigen-speciﬁc IFN- producing spleen derived cells measured by ELISPOT fol-
lowing immunization. Placebo control shown at week 6. Symbols represent mean
(±S.E.) SFU adjusted per 106 cells, (n = 4–8). (C) There was  a signiﬁcant correlationD.A. Kaveh et al. / Vac
reatment groups). Mycobacterial counts were log10 transformed
efore comparison. A Two-tailed correlation analysis was  used to
btain coefﬁcient of determination (r2) from the Pearson correla-
ion coefﬁcient (r). Differences with a p value <0.05 were considered
igniﬁcant and denoted with *, <0.01 with ** and <0.001 with ***.
. Results
.1. BCG-bacilli and -speciﬁc IFN- responses persist for at least
6 months in vaccinated mice and demonstrate a deﬁned
orrelation
To establish the long-term persistence of viable BCG bacilli,
roups of mice were immunized at week 0 with a standard dose
2 × 105 CFU) of the licensed human vaccine BCG Danish 1331. At
equential monthly time-points, the BCG burden of individual mice
as determined in pooled draining lymph nodes (d.LNs), spleen
nd lungs; plating the entire organs/tissues to maximise detection.
ig. 1A demonstrates that viable BCG bacilli were cultured from the
.LNs throughout the experimental duration of 16 months. The bur-
en was highest and most consistent at 6 weeks post immunization
p.i.) at 3.0 log10 CFU (±0.5), decreasing to 2.4 log10 CFU (±0.5) at 16
onths p.i.
BCG were cultured from the majority of spleen samples,
lthough with large replicate variability. CFU counts increased from
.7 log10 CFU (±1.7) at 6 weeks p.i. to 2.3 log10 CFU (±2.3) at 17
eeks p.i., decreasing to 0.0 log10 CFU (±2.0) by 16 months p.i. Cul-
ure of BCG from the lungs was sporadic and only possible in 1 or 2
eplicates at each time point up to 22 weeks p.i., after which it was
ndetected.
Given the established importance of IFN- producing CD4 T
ells in protection against TB, the frequency of BCG-speciﬁc IFN-
 secretors in the spleen was evaluated by ex vivo ELISPOT using
eﬁned protein cocktail at deﬁned time-points following BCG
mmunization. Fig. 1B shows that whilst IFN- secreting cell fre-
uency was maximal at 6 weeks p.i. (1197 SFU/million cells) and
eclined thereafter; substantial frequencies of IFN- secreting cells
478 SFU/million cells) were present 16 months p.i., as previously
escribed [9].
Regression analyses between the mean spleen IFN- ELISPOT
requency and the mean bacterial burden in d.LNs showed a statis-
ically signiﬁcant correlation, demonstrating a clear link between
ntigen load (from the most reliable tissue indicator) and IFN-
esponses circulating through the spleen (Fig. 1C).
.2. Antibiotic treatment abrogates BCG persistence and speciﬁc
FN- effector response
To establish the minimum treatment regimen to clear persistent
acilli after BCG immunization, groups of mice were immunized
ith BCG for 6 weeks (previously shown to induce protection)
9,28]. They were then given a 0, 1, 2 or 3 month course of antibiotic
reatment (subsequently termed BCG abbreviated) of ethambutol,
soniazid and rifampicin via drinking water. Mice were returned
o normal water for a further two weeks following the cessation
f treatment, to ﬂush any residual in vivo antibiotics inhibiting
acterial culture.
At the end of each treatment regimen, bacterial burden in the
ndividual organs/tissues was determined as described previously;
ith the inclusion of the liver as an additional potential reservoir
f bacilli. Fig. 2A shows that 1 month of treatment was sufﬁcient
o clear residual bacilli from the spleen; but a further 2 months of
reatment were required to consistently clear persistent BCG from
he d.LNs in all animals. The pre-treatment burdens observed in
oth the spleen and d.LNs were equivalent to previous experimentsbetween the mean frequency of IFN- producing spleen cells and the mean BCG
bacterial burden in the d.LNs. r2 = correlation analysis coefﬁcient of determination.
(Fig. 2A cf. Fig. 1A). BCG in lungs and liver were undetectable in this
experiment.
As further experiments were critically dependant on con-
sistent efﬁcacy of treatment, a further experiment included
vaccinated mice given an additional 3 months rest after cessa-
tion of 3 months treatment. In contrast to immunised, untreated
mice (which had a burden of 2.7 log10 CFU (±0.6) in the d.LNs
∼7.5 months p.i.), no viable BCG were detected in the treat-
ment group (Fig. 2B) conﬁrming the efﬁcacy of antimicrobial
treatment.
To evaluate the effect of persistent BCG bacilli on speciﬁc IFN-
responses, groups of mice were immunized with BCG or placebo
control for 6 weeks, prior to treatment with antibiotics or placebo
for 3 months. To ensure that: (a) analyses were not inﬂuenced by
short-lived effector T cell responses; and (b) BCG bacilli were effec-
tively cleared, animals were rested for 3 months after treatment.
6914 D.A. Kaveh et al. / Vaccine 3
Fig. 2. Antibiotic treatment abrogates BCG persistence and the speciﬁc IFN- response.
Mice were immunized with BCG for 6 weeks followed by a 1, 2 or 3 month course
of  antibiotic treatment, as indicated. Mice were rested for 2 weeks after cessation of
treatment. (A) mycobacterial burden in whole organ homogenates. (B) In a second
experiment, mycobacterial burden was assessed from the d.LNs 3 months following
cessation of 3 month antibiotic treatment course. Symbols and bars represent mean
(±S.E.) CFU, (LOD = 2 CFU, n = 7–8). (C) IFN- production by ELISPOT of spleen cells
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Tfter a 3 month treatment regimen. Symbols represent mean (±S.E.) SFU adjusted
er  106 cells with placebo responses deducted. *** p < 0.001, students t-test. Data are
epresentative of two  independent experiments (n = 6–8).
he frequency of BCG-speciﬁc IFN- secreting cells in the spleen
as then evaluated by ex vivo ELISPOT stimulated with the deﬁned
rotein cocktail.
Fig. 2C shows that the signiﬁcant IFN- response induced by
CG immunization (613 SFU/million cells) was completely abro-
ated in BCG abbreviated animals (p < 0.001). These data clearly
emonstrate that, the persisting IFN- responses observed in BCG
mmunized animals were due to persistent BCG bacilli, rather than
ong-term memory.
.3. The presence of BCG-speciﬁc multifunctional CD4 TEM cells is
ependent upon the presence of live BCG bacilliTo further investigate whether this ablation of the IFN-
esponses (ELISPOT) in BCG abbreviated mice was speciﬁc to CD4
 cells and of what memory phenotype, the CD4 T cell responses2 (2014) 6911–6918
speciﬁc to BCG in spleen and lung were assessed by intracellular
cytokine staining (ICS) after stimulation with deﬁned protein cock-
tail (Fig. 3). Fig. 3A shows BCG immunization induces signiﬁcant
populations of multifunctional CD4 T cells (IFN-+/IL-2+/TNF-+,
IFN-+/TNF-+ and IL-2+/TNF-+), in both spleen and lung-derived
cells, with frequencies considerably higher in the lungs as reported
previously [9]. ICS performed on d.LN samples of BCG immunized
mice in previous experiments were unable to detect signiﬁcant
populations of cytokine producing cells (data not shown), and
so were not performed here. Consistently, no BCG-speciﬁc CD8
responses were detectable in any of these, or previously reported
experiments [9].
Further, these data demonstrate the clearance of persistent BCG
bacilli signiﬁcantly ablates (p < 0.001) the presence of all cytokine
producing CD4 T cells in both the spleen and lungs (Fig. 3A). Con-
sistent with previous data [9] these multifunctional CD4 T cells
consist entirely of CD44hi CD62Llo cells indicative of a TEM pheno-
type (spleen—99.3%; lung—99.6% of total cytokine+ cells) as shown
in Figs. 3B (representative plots of spleen and lung CD4 T cells) and
S1 (gating strategy).
We considered that the absence of a measurable TCM (CD62Lhi)
response may  be due to the effector cell focus of the assays thus
used. We therefore used a class II MHC  – TB10.4 (73–88 a.a.)
peptide-tetramer complex to detect the total CD4 T cell population
speciﬁc to this immunodominant antigen in spleens of vaccinated
or BCG abbreviated mice, (Figs. 3C and D). As shown in Fig. 3C, 0.23%
of total spleen CD4 T cells were CD62Llo Tet+; reduced to 0.03%
CD62Llo Tet+ following BCG abbreviation (Figs 3C and D). There
were no vaccine-speciﬁc CD62Lhi Tet+ CD4 T cells in the spleen
(Fig. 3C) or LNs (data not shown). Tetramer analysis of lung cells
was not performed due to insufﬁcient yields.
These data demonstrate both systemic and mucosal CD4 T cell
responses to BCG vaccination are dependent on the persistence of
live bacilli, and that these responses are dominated by multifunc-
tional CD4 TEM cells, with no detectable CD4 TCM cells.
3.4. Protection is optimal in the presence of, but not dependant
on, persistent BCG bacilli
To determine the effect of these persistent viable vac-
cine bacilli upon BCG-induced protection; equivalent groups
of mice were subjected to this antibiotic treatment reg-
imen, prior to intranasal challenge with M.  bovis for 4
weeks. As described in Fig. 4, both BCG and BCG abbreviated
immunized mice exhibited signiﬁcant protection compared to
placebo controls in both the spleen (Fig. 4A): BCG—protection
1.6 log10 (p < 0.001); BCG-abbreviated—0.8 (p < 0.001), and the
lungs (Fig. 4B): BCG—protection 1.7 log10 (p < 0.001); BCG-
abbreviated—0.7 (p < 0.01). Protection in BCG-abbreviated mice,
however, was  signiﬁcantly less compared to untreated BCG vac-
cinates (spleen 52% reduction cf. untreated, p < 0.01; lungs 40% cf.
untreated, p < 0.001).
These data demonstrate that whilst BCG induced protection is
optimal when persistent bacilli are present; signiﬁcant protection
is maintained after clearance of these bacilli.
4. Discussion
As BCG remains the benchmark to improve upon, it is critical
to understand the mechanisms underlying its protective efﬁcacy if
improved vaccines or vaccination strategies for TB are to progress.
Primary to this aim must be further investigation on the establish-
ment and maintenance of BCG-induced memory.
We report that intradermal immunization with a relatively low
dose of BCG (2 × 105 CFU) results in a persistent ‘infection’, with
viable vaccine bacilli present in the secondary lymphoid organs
D.A. Kaveh et al. / Vaccine 32 (2014) 6911–6918 6915
Fig. 3. BCG abbreviation abrogates multifunctional CD4 T cell response. Mice were immunized with BCG or placebo control 6 weeks prior to receiving a 3 month course of
antibiotic chemotherapy to abbreviate bacilli persistence. After a further 3 months, lymphocytes from the spleen or lung were isolated, antigen stimulated and stained by
intracellular staining (ICS). Alternately unstimulated cells were stained with speciﬁc MHC  class II-TB10.4 peptide complex tetramer, together with cell surface markers.
(A)  Analysis of the 7 potential combinations of cytokine producers, from the three experimental groups. Bars represent mean (±SE) % frequency of cells of indicated T cell
phenotype as a % of total CD4+ cells. *** p < 0.001, ANOVA with Bonferroni post-test (n = 6–8). Data are representative of two independent experiments. (B) Representative
ﬂow  cytometry plots (spleen/lung cells), from BCG immunized mice, gated on live CD4+ lymphocytes, identifying the antigen-speciﬁc cytokine+ (any combination of: IFN-+ ,
IL-2+ , TNF-+) cells analyzed for CD44 and CD62L expression. Cytokine+ events overlay contours displaying the expression of CD44 and CD62L by all CD4  T cells, numbers
represent CD44hi CD62lo cytokine+ cells as a % of all cytokine+ cells. Data are representative of 6 separate experiments. (C) Representative ﬂow cytometry plots (spleen
cells),  gated on live CD4+ lymphocytes, identifying class II MHC—TB10.4 (73–88 a.a.) peptide-tetramer+ cells analyzed for CD62Llo/hi expression, from the three experimental
g ells. D
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ith  Bonferroni post-test (n = 7).
SLO) for up to 66 weeks. Further, we demonstrate a direct rela-
ionship between the BCG burden and the frequency of IFN-
esponses. We  establish that clearance of these bacilli requires sus-
ained antibiotic treatment, and abrogates the cytokine producing
accine-speciﬁc CD4 T cells derived from the spleen and the lungs.
trikingly, although substantially decreased, signiﬁcant pulmonary
nd systemic protection was still present following clearance of
acilli. Together these data suggest BCG may  induce two  mecha-
isms of immunity: (i) dependant on the presence of viable bacilli
nd associated TEM; and (ii) a further mechanism, independent of
ersisting bacilli and TEM. The exact details of the latter mechanism
re yet to be elucidated, and are the subject of current investiga-
ion.
The question of BCG persistence has been noted in previous
tudies in mice [24,25,27,32–35], other animal models [23,26] and
umans [36,37]. In a similar study using C57BL/6 mice and M. tb
hallenge [27], spleen protection was reduced by 75%, but in con-
rast lung immunity was unaffected. This disparity with our study
ould be due to: mouse strain, challenge organism, incomplete BCG
acilli clearance, or the shorter duration between chemotherapy
nd challenge.
To date, however, no relationship between BCG persistence
nd the predominance of CD4 TEM responses has been reported
9,16,18,38]. Our data indicate a clear link between BCG anti-
en load and T cell responses, which as demonstrated here and
reviously, are multifunctional (IFN-+/IL-2+/TNF-+, IFN-+/TNF-
+ and IL-2+/TNF-+) CD62Ll◦CD4 T cells which we consider TEM
9]. We  also demonstrate that antigen-speciﬁc IFN- could used as
 direct surrogate of viable bacilli (with the caveat of appropriate
ntigen stimulation).ata are representative of 6 separate experiments. (D) Analysis of spleen tetramer+
 control tetramer staining values subtracted (±S.E.). ** p < 0.01, *** p < 0.001, ANOVA
We cannot rule out that our antibiotic regimen did not
completely eliminate the persistent BCG without performing sub-
sequent immunosuppression [39], which was beyond the scope
of our study. However, our data clearly demonstrate reproducible
elimination to a point that no BCG baciili and antigen-speciﬁc cells
could be detected after 3 months of ‘rest’. Therefore, we  consider
this sufﬁcient BCG clearance for the objectives of this study.
We deﬁne these IFN-+/IL-2+/TNF-+ triple- or bi-functional
cells as CD4 TEM based on CD62Llo CCR7− expression [9]. As CD62L
can be cleaved by metalloproteases, we  previously conducted
studies using the inhibitor TAPI-2 [40] to demonstrate that iden-
tiﬁcation of stimulated-responder cells as CD62Llo was not due
to non-speciﬁc mechanisms of CD62L down-regulation (data not
shown). We  have also conﬁrmed this by sorting CD62Llo/hi cells
prior to functional assay (Kaveh & Hogarth, unpublished data).
Following BCG clearance, this absence of CD4 TEM cells, and
indeed any detectable antigen-speciﬁc IFN- responses (ELISPOT)
or cells expressing a T cell receptor (TCR) speciﬁc to an immun-
odominant antigen; indicates that all detectable responses result
from continual priming by BCG bacilli, as has been reported during
chronic Salmonella infection [41], and that they are relatively short-
lived. Whilst determination of speciﬁc CD4 TEM cell longevity was
beyond the scope of this study; they were absent at four months
following last detection of viable bacilli, indicating a lifespan of
<four months; conforming to the hypothesis that TEM cells are
responsible for intermediate, rather than long-term memory [42].
Interestingly, our previous data show lung TEM responses were sus-
tained at 12 months following BCG immunization. [9], at which
point we  show here there are no detectable bacilli in the lung, indi-
cating trafﬁc from a site of active priming such as the SLO; according
6916 D.A. Kaveh et al. / Vaccine 3
Fig. 4. Degree of protection is dependent on the presence of viable BCG. Mice were
immunized with BCG or placebo control 6 weeks prior to receiving a 3 month
course of antibiotic chemotherapy to abbreviate bacilli persistence. After a further
3  months, mice were challenged with M. bovis for 4 weeks and the: (A) spleens and
(B) lungs assayed for M.  bovis bacterial burden. Bars represent mean CFU (±S.E.). **
p < 0.01, *** p < 0.001, ANOVA with Bonferroni post-test (n = 8). The indicated % pro-
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the AHVLA Animal Services Unit.ection is calculated from that observed in BCG immunized (non-abbreviated) when
ompared to placebo control mice.
ith reports that responses to mycobacteria are initiated in the LN
43,44].
Despite their short-lived nature, CD4 TEM cells appear to make a
igniﬁcant contribution to protective immunity, as the reduction
n bacterial burden was reduced by up to 60% in their absence.
D4 TEM have been reported as important mediators of protection
n M.  tuberculosis [45] malaria [46] and Leishmania [38], among
ther infections. We  acknowledge, however, that a direct protec-
ive, rather than associative role of these cells remains to be shown;
ut at present, the lack of technologies to allow the sorting of live
 cells based on cytokine production, preclude the TEM adoptive
ransfer experiments required to deﬁnitively demonstrate such a
ole.
It is intriguing to speculate whether at least a proportion of the
rotection afforded by BCG during childhood is due to persisting
acilli and associated TEM. There is evidence that BCG may  per-
ist for many years in humans [37,47–52] and together with the
bserved waning of immune responses to BCG through childhood
36]; this may  represent gradual clearance of bacilli and associated
 cells.
Long-term memory, however, is considered dependent on the
eneration of TCM responses. At present, few reports directly iden-
ify an antigen-speciﬁc CD4 TCM cells induced in mice by BCG
lone [19,22]; some describe TCM-like cells after clonal expan-
ion induced by prime-boost vaccination, challenge or reinfection
14,21,53]. In humans, TCM may  only appear after contraction of
he BCG-speciﬁc TEM response [20]. This situation is confounded by
ur incomplete understanding of TCM cell phenotypes. Conﬂicting
vidence is often published, and there is clearly substantial plas-
icity between memory T cell phenotypes (reviewed in [42,54]).
nequivocal identiﬁcation of these cells is also complicated by the
eak expression of characterisitic cells markers (e.g. CCR7) and
heir often mutual expression by the naïve T cell population.2 (2014) 6911–6918
ICS by ﬂow cytometry is often used, but has a distinct effector
bias relying immediate cytokine production, and so is unlikely opti-
mal  for TCM detection [55,56]. To circumvent this, we performed
class II-peptide tetramer staining, but were unable to detect any
CD4+CD62Lhi antigen-spepciﬁc TCM cells. Perhaps the paucity of
reported TCM responses to vaccination is due to rarity of these cells,
estimated at 0.025–0.0025% of total CD4 T cells [57]. The back-
ground responses of most assays in naïve mice (<0.05% CD4 T cells)
may obscure such populations [57]. Indeed, recent studies have had
to employ enrichment of tetramer+ cells [58], to allow detection of
rare TCM cells in BCG vaccinates [19,22]. Other in vitro expansion
approaches, such as cultured ELISPOT [59] may  also help to resolve
this population.
Therefore, we cannot rule out the existence of undetected
BCG-speciﬁc TCM. The existence of potential TCM cells has been
demonstrated in adoptive-transfer experiments, where cells with
a potential TCM phenotype (CD62Lhi/CD45RBhi, but unknown for
CCR7) conferred modest protection [12,60].
In the absence of a robust TCM response, other potential mecha-
nisms of protection in BCG abbreviated mice may include alternate
T cell subsets secreting cytokines not examined in this study (e.g.
TH17 [13]), or undetected CD8 T cells, B cells or ‘innate’ cell activa-
tion and imprinting [61].
Current models for assessing TB vaccines compare performance
against the BCG ‘gold standard’, which likely include persistent
bacilli and thus active TEM responses. This may  account for the
inability to improve upon BCG often reported [62]. A model where
protection is assessed against only long-term memory, such as the
abbreviation method used here, or other strategies to remove con-
stant priming; may  allow an enhanced ‘window of protection’ and
subsequent identiﬁcation of vaccines with potential for improved
performance.
This report has implications for the interpretation of immunity
in pre-clinical models, with predominant responses dependent on
antigen persistence. Therefore, studies which include such per-
sistent BCG, not only demand a vaccine candidate to outperform
the ‘gold standard’ in the face of constantly primed TEffector and
TEM responses; but also confound interpretation of the immuno-
logical analyses, with the dominant responses induced by live
BCG undoubtedly obscuring the immune responses responsible
for long-term memory-mediated protection. This underscores the
importance of understanding the mechanisms of T cell memory.
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